Bromocriptine for unexplained subfertility in women (Cochrane Review)

A substantive amendment to this systematic review was last made on 21 July 1994. Cochrane reviews are regularly checked and updated if necessary.

Background: Bromocriptine improves hyperprolactinemic amenorrhea and so could also be helpful in the treatment of unexplained subfertility in women.

Objectives: To assess the effects of bromocriptine in women with unexplained subfertility.

Search strategy: The Cochrane Subfertility Review Group specialised register of controlled trials was searched.

Selection criteria: Randomised trials comparing bromocriptine with placebo or no treatment in women with unexplained subfertility.

Data collection and analysis: Two reviewers applied the eligibility criteria and assessed trial quality independently.

Main results: Three trials involving of 127 women were included. All trials were double-blind comparisons with placebo, and one was of crossover design. Conception rates with bromocriptine treatment did not improve compared with placebo (odds ratio was 1.12, 95% confidence interval 0.48 to 2.57).

Reviewers' conclusions: There is not enough evidence to evaluate bromocriptine use in women with unexplained subfertility. However trials for women with unexplained subfertility who also have expressible galactorrhea may be worthwhile.[This abstract has been prepared centrally.]

Citation: Hughes E, Collins J, Vandekerckhove P. Bromocriptine for unexplained subfertility in women (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.

---

This is an abstract of a regularly updated, systematic review prepared and maintained by the Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).

The Cochrane Library is designed and produced by Update Software Ltd.

Update Software Ltd, Summertown Pavilion, Middle Way, Oxford OX2 7LG, UK
(Tel:+44 1865 513902; Fax:+44 1865 516918)

File Reference: AB000044.htm